satralizumab   

GtoPdb Ligand ID: 9093

Synonyms: SA-237 | SA237 | sapelizumab (perviously known as)
Compound class: Antibody
Comment: Satralizumab (previously referred to using the replaced INN sapelizumab) is an investigational humanized monoclonal antibody targeting the IL-6 receptor, with immunomodulatory potential. This antibody is an improved version of tocilizumab, with enhanced antigen-neutralizing ability and pharmacokinetics suitable for less frequent administration [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide BLAST searches reveal identical matches between the heavy and light chain sequences as annotated in IMGT and SEQ IDs 26 and 29 respectively claimed in patent US8562991 [1]. This matches satralizumab to the Fv4-M73 construct in the patent.
No information available.
Summary of Clinical Use
Satralizumab (using research code SA237) has reached Phase III clinical trial for the treatment of neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) (see NCT02073279). It was granted EMA orphan drug designation for NMO in June 2016.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02073279 Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Interventional Hoffmann-La Roche